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Prostate cancer is a very common malignancy in 
many countries. In the USA it accounts for almost a 
third (31.2%) of all cancers, ranking second only to 
lung cancer as the cause of death in men (11.7%). [1] 
There seems to be a paucity of evidence regarding 
the epidemiology of prostate cancer in sub-Saharan Africa.[2-3] It 
is, however, known that men of African descent appear to suffer 
disproportionately more from prostate cancer compared with men of 
other races or ethnicities,[4] and present with more advanced disease.[5-8]
To date most, if not all, of the epidemiological studies on prostate 
cancer in South Africa (SA) have been undertaken by Heyns and 
colleagues in the Western Cape Province,[5,9-13] and their findings have 
influenced national guidelines and policy. However, it remains to be 
established whether these findings are consistent among the various 
provinces of SA, in part because of different racial composition and 
socioeconomic status of populations.
With the imminent roll-out of National Health Insurance (NHI) in 
SA, there is a need to quantify the burden of prostate cancer on the health 
service. In a resource-deprived setting such as KwaZulu-Natal Province 
(KZN), human resources and infrastructure need to be allocated 
appropriately to enhance the quality of care that patients receive.[14] 
There is currently no literature in SA regarding how long patients with 
suspected prostate cancer wait to have a prostate biopsy in the public 
healthcare sector, and how long they wait to initiate treatment.
Objectives
To form a framework to improve the overall efficiency of the prostate 
biopsy service at St Aidan’s Hospital, Durban, which serves as a 
specialist urology referral centre. We described the patient profile, 
referral pattern and pathological burden of disease, calculated the 
waiting period in days from peripheral hospital referral to biopsy 
date, and attempted to identify high-risk groups in which referral 
should be expedited and to identify potential delays in management.
Methods
A retrospective folder review of patients who had undergone trans-
rectal prostate biopsy for clinically suspected prostate cancer was 
undertaken at the Urology Cinic at St Aidan’s Hospital from January 
2013 to June 2013. Patients were referred to the service directly 
from peripheral health facilities and local hospitals in the eThekwini 
district, KZN.
All patients had sextant trans-rectal ultrasound-guided (TRUS) 
biopsies for the first time, and only those with confirmed histological 
findings were included.
The study was three-tiered and aimed at defining the scope of the 
burden of disease on the service, calculating the waiting times and 
describing the referral patterns. Patients self-assigned their race as 
black African, white, Indian or coloured (of mixed ancestry).
Time intervals were calculated from dates obtained from referral 
notes. Three different time intervals were calculated: (i) from referral 
to biopsy, i.e. the number of days a patient waited to receive a biopsy 
after being referred to the service; (ii) from referral to first follow-
up, i.e. the number of days a patient waited to receive a histological 
diagnosis, and for treatment options to be discussed or instituted; 
and (iii) from biopsy date to first follow-up date, i.e. waiting period to 
retrieve a histological diagnosis, or histology processing time.
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Background. There is currently no evidence in the South African (SA) literature to suggest how long patients with clinically suspected 
prostate cancer (an elevated prostate-specific antigen level or abnormal findings on digital rectal examination) wait to have a prostate 
biopsy.
Objectives. To improve the overall efficiency of the prostate biopsy service offered at St Aidan’s Regional Hospital, Durban, SA, by 
quantifying the burden of disease and waiting times and to identify potential delays in management outcomes, thereby helping to alleviate 
patient anxiety during the stressful period of investigation.
Methods. We did a retrospective folder review of patients who underwent trans-rectal prostate biopsy at St Aidan’s Hospital, where the vast 
majority of prostate biopsies in the KwaZulu-Natal state healthcare sector are performed, from January to June 2013. The Statistical Package 
for Social Sciences was used for data analysis.
Results. One hundred and six patients (mean age 67.6 years, 69.8% black Africans) underwent biopsy during the 6-month study period; 
49.1% were found to have adenocarcinoma, and of the 80.1% of these who had a bone scan, 73.8% had skeletal metastases (p=0.1379). The 
median period of time from referral to biopsy was 55 days, from referral to first follow-up date (when the diagnosis is given and treatment 
options discussed or instituted) 100 days, and from biopsy to first follow-up date (i.e. waiting period to retrieve histological diagnosis) 36 
days.
Conclusion. Despite the late presentation of prostate cancer in KZN, patients are waiting an average of 3 months from initial referral for a 
prostate biopsy to institution of definitive management.
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Because of incomplete and manual record keeping, we were unable to 
do accurate clinical staging according to the 2002 TNM classification. 
However, patients were risk-stratified according to the D’Amico 
risk stratification,[15] using prostate-specific antigen (PSA) in most 
instances. Haematogenous metastases were detected by skeletal 
scintigraphy (bone scan). Indications for prostate biopsy included 
a serum PSA level >4 ng/mL or suspicious findings on digital rectal 
examination (DRE).
Statistical analysis
Data were captured using Microsoft Excel and analysed using the 
Statistical Package for Social Sciences (SPSS version 21) in consultation 
with a biostatistician. Comparison of means was performed using 
Student’s t-test for parametric data and the Mann-Whitney and Kruskal-
Wallis tests for non-parametric data. Fisher’s exact test was used for 
contingency table analysis. A two-tailed p-value of <0.05 was accepted as 
statistically significant.
Ethical approval
Ethical approval for the study was granted by the University of 
KwaZulu-Natal Biomedical Research Ethics Committee and the 
KwaZulu-Natal Provincial Health and Research Ethics Committee.
Results
One hundred and six patients (mean age 67.6 years (standard 
deviation 7.51)) underwent TRUS biopsy. Of these patients, 69.8% 
(n=74) were classified as black, 4.7% (n=5) as white, 13.2% (n=14) as 
Indian and 12.3% (n=13) as coloured.
Almost half of the patients (49.1%, n=52) were found to have 
adenocarcinoma. Other findings included benign prostatic hyperplasia, 
prostatitis, and inadequate speci men for analysis. The distribution 
of histological findings is illustrated in Fig. 1. The majority of 
malignancies (75.0%, n=39) were found in black patients (Fig. 2).
According to the D’Amico risk strati fication, 68.9% (n=51) of black 
patients were classified as high risk v. 4.7% of whites (n=5), 13.2% of Indians 
(n=14) and 12.3% of coloureds (n=13), which was statistically significant 
(p<0.001). The median PSA level (Fig. 3) of black African patients with 
prostate cancer was 42.2 ng/mL v. 12.8 ng/mL for whites, 10.3 ng/mL 
for Indians and 14.2 ng/mL for coloureds, which was also statistically 
significant (p<0.001). The median PSA level of patients with confirmed 
carcinoma was 133.5 ng/mL, as opposed to 16.0 ng/mL for those without 
cancer (p<0.01). A relationship was observed between initial PSA level 
and Gleason score (p=0.01). We were unable to stage patients according to 
the TNM classification, as in 36.8% of folders the DRE findings were not 
adequately documented. Of the 52 patients with histologically confirmed 
adenocarcinoma, 80.1% (n=42) received a bone scan; in 73.8% (n=31) 
skeletal scintigraphy confirmed metastases, 8 (18.6%) had no metastases, 
and 4 (9.3%) had equivocal findings (p=0.1379).
With regard to treatment modalities, 92.5% of patients (n=98) 
received some form of medication; only 8.5% (n=9) underwent 
surgical intervention, while 4.7% (n=5) received external-beam 
radiation. Medication included alpha-blockers (n=32), antibiotics 
(n=4), androgen-deprivation therapy (ADT) (n=47) and combination 
regimens (n=62). Of the patients with confirmed adenocarcinoma, 
90.4% received ADT.
The majority of referrals (59.4%, n=63) were from the King 
Edward VIII Hospital (KEH) complex, 22.6% were from Adding ton 
Hospital (AH), 16.0% were from R K  Khan Hospital (RKKH), and 
only 1.9% were from private practitioners. Of those with confirmed 
prostate adenocarcinoma (n=52), 55.8% (n=29) were referred from 
KEH, 25.0% (n=13) from AH, 17.3% (n=9) from RKKH and 1.9% 
(n=1) from private practice.
The median period of time from referral to biopsy date was 55 days, 
from referral to first follow-up date 100 days, and from biopsy date 
to first follow-up date 36 days (Fig. 4). No relationship was observed 
between referral centre and any of the waiting periods (p>0.05).
Discussion
The patients in this study were more representative of the demograph-
ics of the general SA population than the larger 10-year retrospective 
review of 901 patients with prostate cancer managed by the urological 
oncology clinic at Tygerberg Hospital, Western Cape, by Heyns et 
al.[5,16] The Western Cape study[5] demonstrated a predominance 
(59.8%) of white patients with prostate cancer, black patients account-
ing for only 32.3%. This differs from the findings of our study, in 
which there was a predominance of blacks (69.8%, n=74), and whites 
accounted for only 13.2% (n=14). The median PSA level of our black 
patients with prostate cancer was 42.2 ng/mL (n=74) and that for 
whites was 12.8 ng/mL (n=5), in comparison with findings in the 
Western Cape[5] of 105 ng/mL and 19.6 ng/mL, respectively.
Owing to the lack of understanding of the disease profile in KZN, 
and lack of an updated National Cancer Registry, it is very difficult 
to draw guidelines, allocate resources and streamline biopsy services 
with the aim of establishing an efficient service and identifying curable 
disease. Patients are waiting for an average of 3 months (100 days) 
from the initial referral date to presumed diagnosis and definitive 
Fig. 1. Categorisation of histological outcomes.
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management, with only 7.7% (n=4) with prostate cancer qualifying 
for a potentially curative procedure. It is diffi cult to comment on 
this figure further, as lack of adequate record keeping was a major 
challenge and patients could not be staged adequately. However, 
almost two-thirds (n=31) of patients with confirmed adenocarcinoma 
were found to have had advanced disease at presentation. A future 
larger prospective study should be performed in KZN, similar to that 
of Heyns et al.,[9] who found that potentially curative treatment could 
be offered to 37.5% of patients with clinically localised prostate cancer.
Postulated reasons for the delay in diag nosis include but are not 
limited to patient, healthcare provider and infrastructure factors 
(Table 1).
Conclusion
Before this study, we were uncertain of the scope of pathology 
encountered at the St Aidan’s Hospital complex. We found that almost 
half of all patients referred to our service have prostate cancer, and 
that almost two-thirds of those with histological confirmation of 
prostate cancer will have metastatic disease at presentation. As shown 
in other larger studies,[5] the vast majority of black patients with 
prostate cancer present with high PSA levels, indicating advanced 
disease in most cases. Patients are waiting an average of 3 months to 
receive a diagnosis and plan of treatment after being referred.
As the number of patients increases with the arrival of NHI, 
waiting times for treatment are likely to continue to increase, 
potentially resulting in additional treatment delays.
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Fig. 4. Waiting times for the different time intervals observed.
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Table 1. Reasons for delay in diagnosis
Patient factors Healthcare provider factors Infrastructure factors 
• Lack of personal health awareness 
• Only seeking medical intervention 
when symptomatic or traditional 
medicine has failed 
• Inadequate gatekeeper knowledge of DRE, 
PSA screening and when to appropriately 
refer 
• Belief that prostate cancer is a slowly 
progressive disease that does not need to be 
referred timeously 
• Lack of dedicated prostate biopsy clinics
• Lack of equipment – ultrasound machines with 
rectal probes and biopsy needles 
• Overbooked clinics 
• Lengthy pathology processing time 
• Inadequate human resource training and allocation 
